Status
Conditions
Treatments
About
The U.S. Centers for Disease Control and Prevention has recommended the male latex condom as the best physical barrier for preventing HIV and sexually transmitted disease (STD) transmission. Condoms are a safe and effective form of contraception that have 98% effectiveness in protecting against STD and pregnancy. However, evidence shows that if a condom does not fit properly, its impact can reduce to 85% or less, as it may slip off during sex or during removal of the penis from the vagina or breaks during intercourse.
Condoms need to fit correctly to guard against fluids and exposed skin which could lead to STD contraction or pregnancy. To choose the right size, the girth (the width of an erect penis) is the most important factor, not length. However, most condom companies do not list their nominal width, let alone base their sizes off girth. In addition, most brands usually offer XL as only 56 mm based on a misconception that one size fits all and that "XL" condoms are big enough. But that is far from the truth, and several men complain about the lack of simplicity and intuitiveness when finding a condom that fits them.
To address this gap, after a long two years of development, Titan company was able to engineer four distinct sizes so that each man can easily find the condom he needs. This study aims to obtain a preliminary estimate of slippage and breakage of Titan's new condom (64mm or 69mm) during use.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Couples not at risk of pregnancy (using alternate contraception).
Couples who are past or recent/experienced condom users
No known sexually transmitted infections, including HIV/AIDS, gonorrhea, chlamydia, etc.
Subjects between 18 to 45 years of age.
Monogamous heterosexual couples who agree to practice vaginal sex only during the study.
The Titan Size Guide will be used to determine subject eligibility based on the following penis girth measurements
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
100 participants in 2 patient groups
Loading...
Central trial contact
Niloofar Taghizadeh, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal